Completed PHASE4 INTERVENTIONAL NCT01041040

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Sponsor: PETHEMA Foundation

Conditions Acute Myeloblastic Leukemia

Interventions gemtuzumab

Updated 5 times since 2017 Last updated: Jul 30, 2013 Started: Oct 31, 2007 Primary completion: Dec 31, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Acute Myeloblastic Leukemia, this trial is completed. The trial is conducted by PETHEMA Foundation and has accumulated 5 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PETHEMA Foundation

Data source: PETHEMA Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valencia, Spain